Iqvia Holdings Inc.
IQVQ2 2022(IQV Q1 FY2022)Estimated2.5% AI
AI Revenue %
2.5%
AI Fair Value
$386.3M
AI Revenue (Q)
$89.2M
Total Revenue (Q)
$3.6B
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
IQVIA does not disclose AI-specific revenue. The Technology & Analytics Solutions (TAS) segment ($1,439M, 40.3% of total $3,568M) includes data subscriptions, analytics platforms, and technology services. Only a subset leverages modern AI/ML (e.g., Connected Intelligence platform, AI-driven clinical trial optimization). Conservatively estimating ~6% of TAS revenue ($86M) is attributable to AI-powered products, yielding ~2.4% of total revenue, rounded to 2.5%.
Analyzed by claude-opus-4-6
Quoted Figures
Technology & Analytics Solutions revenues $1,439M; Total revenues $3,568M for Q1 2022
10-Q filed 2023-03-31, Segment Data (prior-year comparative)
IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise.
10-K filed 2022-12-31, Item 1 Business
AI Products Identified (Ring 1)
IQVIA Connected IntelligenceAnalytics-driven clinical development (AI site identification, patient recruitment)Real world solutions ecosystem (retrospective analytics, NLP)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Traditional data subscriptions and information servicesLegacy analytics platforms (pre-AI statistical tools)Contract sales servicesClinical trial management (non-AI workflows)
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix